Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:07 PM ET 10-Q
Financial Results Denali Therapeutics Inc. DNLI

Denali Therapeutics Q3 2026 Results: Turns Profitable, Net Income $70.1M

Denali Therapeutics reported a net income of $70.1 million for the third quarter of 2026, driven by a $194.0 million gain from the sale of a priority review voucher. However, the company recorded a net loss of $185.9 million for the first nine months of 2026, reflecting ongoing heavy investment in research and development and the initial recognition of product revenue.

Key figure
Net income $70.1M
4:07 PM ET 10-Q
Financial Results Hamilton Lane INC HLNE

Hamilton Lane Q2 2026 Results: Net Income $77.5M, Up 9.3% YoY

Hamilton Lane reported its financial results for the quarter ended September 30, 2026, as a large accelerated filer. As of October 30, 2026, the company had 43,993,851 Class A and 11,761,471 Class B shares outstanding. The filing includes condensed consolidated financial statements and notes covering the three and six months ended September 30, 2026.

Key figure
Net income $77.5M · +9.3% YoY
4:07 PM ET 10-Q
Financial Results Live Oak Bancshares, Inc. LOB

Live Oak Bancshares Q3 2026 Results: Net Income $26.4M, Down 0.6% YoY

Live Oak Bancshares reported net income of $26.3 million for the third quarter of 2026, with total assets growing to $16.97 billion. While net interest income increased year-over-year, the company significantly increased its provision for credit losses to $54.7 million compared to $22.2 million in the prior year's quarter.

Key figure
Net income $26.4M · -0.6% YoY
4:07 PM ET 8-K
Financial Results Tarsus Pharmaceuticals, Inc. TARS

Tarsus Pharmaceuticals Financial Results

Tarsus Pharmaceuticals reported record third quarter 2026 financial results, highlighted by XDEMVY net product sales of $194.6 million, a 64% year-over-year increase. The company surpassed one million bottles dispensed and $1 billion in cumulative net sales since the product's launch, while also announcing the appointment of Neera Clase as Chief Commercial Officer.

“XDEMVY has shown what that focus can achieve. In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started. That strength is helping us build one of the most differentiated pipelines in eye care, with the potential to bring five medicines to patients in the next five years.”

Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus
4:07 PM ET 10-Q
Financial Results SLR Investment Corp. SLRC

SLR Investment Q3 2026 Results: Net Income $7.58M, Down 67.5% YoY

For the nine months ended September 30, 2026, SLR Investment Corp. reported net investment income of $53.4 million, a decrease from $65.3 million in the prior year period. Total net assets declined to $972.8 million, resulting in a Net Asset Value (NAV) per share of $17.83 compared to $18.26 at the end of 2025.

Key figure
Net income $7.58M · -67.5% YoY
4:07 PM ET 8-K
Financial Results Procore Technologies, Inc. PCOR

Procore Technologies Financial Results

Procore Technologies reported Q3 2026 revenue of $402 million, up 19% year-over-year, exceeding the high end of its guidance. The company achieved a non-GAAP operating margin of 23% and raised its full-year 2026 revenue outlook to a range of $1.557 billion to $1.559 billion.

Term
Q3 2026

“Q3 was another outstanding quarter, with revenue and margins above the high end of our guidance. We delivered new capabilities across our flagship products and made Procore AI’s digital coworkers generally available. We are well on our way to becoming a next-generation, AI-native construction management platform and a true system of intelligence for construction.”

Ajei Gopal, President and CEO of Procore

“Our Q3 performance reflects continued excellent execution across our core business, with revenue up 19%, including 2 percentage points from DroneDeploy. Driven by that underlying momentum, we are raising our full-year revenue and margin outlook, reinforcing our commitment to durable, profitable growth and compounding free cash flow per share.”

Rachel Pyles, CFO of Procore
4:07 PM ET 10-Q
Financial Results Mirum Pharmaceuticals, Inc. MIRM ▶ Call

Mirum Pharmaceuticals Q3 2026 Results: Net Loss of $40.8M

Mirum Pharmaceuticals reported a significant net loss of $898.1 million for the nine months ended September 30, 2026, primarily driven by $756.2 million in acquired in-process research and development expenses. Despite the loss, net product sales grew to $521.8 million for the same period, up from $372.4 million in the prior year.

Key figure
Net loss $40.8M
4:07 PM ET 8-K
Financial Results Weyco Group Inc WEYS

Weyco Group Financial Results

Weyco Group reported third quarter 2026 net sales of $77.0 million, a 5% increase year-over-year, driven by record-breaking wholesale performance from the Florsheim brand. The company also declared a significant special cash dividend of $2.00 per share in addition to reporting a 72% increase in diluted EPS to $1.19.

Term
Q3 2026

“Our third quarter sales were up across North America, led by our Florsheim brand, and supported by solid performances from our Stacy Adams and BOGS brands. Florsheim continued its exceptional momentum, delivering another record-breaking quarter at wholesale, surpassing the brand's prior third-quarter sales record set last year. Sales growth and improved gross margins drove strong profitability for the quarter, further enhanced by tariff refunds. Looking ahead, we remain focused on driving continued sales growth and maximizing profitability across our business lines.”

Thomas W. Florsheim, Jr., Chairman and CEO
4:06 PM ET 10-K
Financial Results Phoenix Education Partners, Inc. PXED ▶ Call

Phoenix Education Partners FY 2026 Results: Net Income $88.9M, Down 33.6% YoY

Phoenix Education Partners, Inc. faces significant regulatory risks, deriving 88.6% of its revenue from Title IV federal student aid. The company is subject to strict compliance requirements including the 90/10 Rule, Borrower Defense to Repayment regulations, and institutional accreditation standards which could materially impact its financial sustainability if violated.

Key figure
Net income $88.9M · -33.6% YoY
4:06 PM ET 10-Q
Financial Results Flux Power Holdings, Inc. FLUX ▶ Call

Flux Power Holdings Q1 2026 Results: Net Loss of $3.2M, Loss Widens

Flux Power reported a significant revenue decline to $6.8M for the quarter ended September 30, 2026, compared to $13.2M in the prior year, leading to a net loss of $3.2M. The company highlighted substantial risks including an event of default under its credit facility with Gibraltar Business Capital and concerns regarding its ability to continue as a going concern.

Key figure
Net loss $3.2M
4:06 PM ET 10-Q
Financial Results Calix, Inc CALX ▶ Call

Calix Q3 2026 Results: Net Income $10.2M, Down 34.7% YoY

Calix, Inc. reported total revenue of $301.7 million for the third quarter of 2026, a 13.7% increase year-over-year, driven by growth in both appliance and software/service segments. Net income for the nine months ended September 26, 2026, rose significantly to $38.5 million compared to $10.7 million in the prior year, despite a substantial $290.2 million cash outflow for common stock repurchases.

Key figure
Net income $10.2M · -34.7% YoY
4:06 PM ET 8-K
Leadership Change Concord Acquisition Corp II CNDA

Concord Acquisition Corp II Leadership Change

Michele Cito resigned as Chief Financial Officer of Concord Acquisition Corp II effective October 28, 2026. The board appointed Charles Coop, currently Vice President of Finance at Atlas Merchant Capital LLC, to succeed her as CFO on the same date.

4:06 PM ET 8-K
Investor Presentation Peoples Bancorp Inc PEBO

Peoples Bancorp Investor Presentation

Peoples Bancorp Inc. management, including the CEO and CFO, will conduct meetings with investors and analysts between November 3 and December 31, 2026. The company filed its 3rd Quarter 2026 Investor Presentation as an exhibit to assist with the understanding of its business and financial performance.

4:06 PM ET 8-K
Financial Results Amgen Inc AMGN

Amgen Financial Results

Amgen reported third quarter 2026 financial results with total revenues increasing 8% year-over-year to $10.4 billion, driven by volume growth across its commercial portfolio. GAAP EPS rose 19% to $7.08, while the company generated $3.7 billion in free cash flow during the period.

Term
Q3 2026

“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”

Robert A. Bradway, chairman and chief executive officer
4:06 PM ET 8-K
Financial Results Angi Inc. ANGI

Angi Financial Results

Angi Inc. reported Q3 2026 financial results with revenue of $242.0 million, a 9% year-over-year decrease, and net earnings of $1.3 million. The company also announced a workforce reduction of approximately 300 roles aimed at generating $50-$60 million in annual run-rate savings to improve organizational velocity and profitability.

Term
Q3 2026

“Angi has one of the most recognized brands in home services, a large network of Pros and an enormous market opportunity. My first 45 days have reinforced my conviction in the potential of this business. We're building on the work already underway to simplify how we operate, move faster and develop better products using technology and AI. I see significant opportunities to improve profitability and cash flow in the near term while building a stronger company positioned for long-term growth.”

Mike Steib, Chief Executive Officer of Angi
4:06 PM ET Form 4
Insider Selling Artiva Biotherapeutics, Inc. ARTV

Artiva Biotherapeutics Chief Tech Operations Officer Christopher Horan Sells $43.6K of Stock

Christopher Horan, Chief Tech Operations Officer, sold 10,423 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $43.6K in total on Nov 2, 2026. Shares held after the trade: 302,321 (-3.3%).

Value
$43.6K
Shares
10,423
Price
$4.18
Role
Chief Tech Operations Officer
Holding change
-3.3%
Trade date
Nov 2, 2026
4:06 PM ET Form 4
Insider Selling Extreme Networks Inc EXTR

Extreme Networks President and CEO Edward Meyercord Sells $1.13M of Stock

Edward Meyercord, President and CEO, sold 50,000 shares of Extreme Networks Inc at $22.57 a share, worth $1.13M in total on Nov 2, 2026. Shares held after the trade: 1,660,097 (-2.9%).

Value
$1.13M
Shares
50,000
Price
$22.57
Role
President and CEO
Holding change
-2.9%
Trade date
Nov 2, 2026
4:06 PM ET 8-K
Shareholder Meeting Scienture Holdings, Inc. SCNX

Scienture Holdings Shareholder Meeting

Scienture Holdings held its 2026 Annual Meeting of Stockholders on October 28, 2026, where shareholders voted on four key proposals. Stockholders elected five directors to the board, ratified CM3 Advisory as the independent auditor for fiscal year 2026, and approved executive compensation on a non-binding advisory basis.

4:06 PM ET 8-K
Financial Results Ssr Mining Inc. SSRM

Ssr Mining Financial Results

SSR Mining reported Q3 2026 net income of $94.8 million and adjusted net income of $130.7 million, driven by production of 103,585 gold equivalent ounces. The company maintained its full-year production guidance but noted that AISC is expected to trend 10% above the original guidance range due to inflation and mine resequencing. SSR Mining also declared a quarterly dividend of $0.03 per share and highlighted its strategic repositioning to an Americas-focused producer following the sale of its Hod Maden stake.

Term
Q3 2026
4:06 PM ET 10-Q
Financial Results Stoke Therapeutics, Inc. STOK

Stoke Therapeutics Q3 2026 Results: Net Loss of $73.6M, Loss Widens

For the nine months ended September 30, 2026, Stoke Therapeutics reported a net loss of $185.3 million, a significant reversal from a net income of $51.0 million in the prior year period, primarily due to a sharp decrease in revenue from $183.0 million to $26.8 million. Operating expenses rose substantially, with research and development costs increasing by 55% to $149.0 million as the company advances its clinical programs for zorevunersen.

Key figure
Net loss $73.6M
4:06 PM ET 8-K
Loan & Debt Ocean Power Technologies, Inc. OPTT

Ocean Power Technologies Debt Financing Update with Vanquish Funding Group Inc.

Ocean Power Technologies entered into a Securities Purchase Agreement with Vanquish Funding Group for a 12% promissory note in the principal amount of $373,750. The agreement includes potential additional tranches of financing up to $2.875 million over the next twelve months and allows for conversion into common stock only upon an event of default.

Counterparty
Vanquish Funding Group Inc.
Term
through Oct 2027
4:06 PM ET 8-K
Loan & Debt BWX Technologies, Inc. BWXT

BWX Technologies $1.25B Debt Financing with Wells Fargo Bank, National Association

BWX Technologies entered into an amendment to its existing credit agreement to extend the maturity of its $1.25 billion senior secured revolving credit facility by one year to November 10, 2031. The amendment also modifies the minimum interest coverage ratio requirements and introduces a new pricing grid tied to the company's corporate credit ratings.

Value
$1.25B
Counterparty
Wells Fargo Bank, National Association
Term
through Nov 2031
4:06 PM ET 10-Q
Financial Results SLR Private Credit BDC II LLC

SLR Private Credit BDC II Q3 2026 Results: Net Income $393K, Up 12.0% YoY

For the nine months ended September 30, 2026, SLR Private Credit BDC II LLC reported total investment income of $3.79 million and net investment income of $1.49 million. The company's net asset value per unit increased to $16.37 from $16.01 at the end of 2025, while total unitholders' capital grew to $19.54 million despite $0.8 million in distributions.

Key figure
Net income $393K · +12.0% YoY
4:06 PM ET 10-Q
Financial Results Ardelyx, Inc. ARDX

Ardelyx Q3 2026 Results: Net Loss of $737K, Loss Narrows

For the nine months ended September 30, 2026, Ardelyx reported total revenues of $343.0 million, a significant increase from $282.1 million in the prior year period, driven primarily by net product sales of IBSRELA and XPHOZAH. Despite the revenue growth, the company recorded a net loss of $55.1 million for the first nine months of 2026, though this was an improvement over the $61.2 million net loss in the same period of 2025.

Key figure
Net loss $737K
4:06 PM ET 8-K
Dividend PennantPark Floating Rate Capital Ltd. PFLT

PennantPark Floating Rate Capital Dividend

PennantPark Floating Rate Capital Ltd. declared a monthly distribution for November 2026 of $0.0833 per share. The distribution consists of an $0.08 base dividend and a $0.0033 supplemental dividend, payable on December 1, 2026, to stockholders of record as of November 13, 2026.

4:06 PM ET Form 4
Insider Selling Nextera Energy Inc NEE

Nextera Energy EVP, Finance & CFO Michael Dunne Sells $585K of Stock

Michael Dunne, EVP, Finance & CFO, sold 6,888 shares of Nextera Energy Inc at $85.00 a share, worth $585K in total on Nov 2, 2026. Shares held after the trade: 64,063 (-9.7%).

Value
$585K
Shares
6,888
Price
$85.00
Role
EVP, Finance & CFO
Holding change
-9.7%
Trade date
Nov 2, 2026
4:06 PM ET 10-Q
Financial Results SCP Private Credit Income BDC LLC

SCP Private Credit Income BDC Q3 2026 Results: Net Income $2.9M, Down 30.4% YoY

SCP Private Credit Income BDC LLC reported a net increase in unitholders' capital resulting from operations of $2.6 million for the nine months ended September 30, 2026, down from $7.0 million in the prior year period. The company's net asset value per unit decreased to $9.01 from $9.42 at the end of 2025, primarily driven by net unrealized losses on investments and distributions to unitholders.

Key figure
Net income $2.9M · -30.4% YoY
4:06 PM ET 8-K
Partnership Profound Medical Corp. PROF

Profound Medical Partnership with Cook Medical Holdings LLC

Profound Medical entered into a supply and distribution agreement with Cook Medical to appoint them as a non-exclusive distributor of the TULSA-PRO system in the U.S. The partnership integrates TULSA-PRO into Cook's Copernicus program for intraoperative MRI suites, expanding Profound's sales channels while retaining direct recurring revenue from disposables and service.

Counterparty
Cook Medical Holdings LLC
Term
5 years
4:06 PM ET 8-K
Loan & Debt Fathom Holdings Inc. FTHM

Fathom Holdings Debt Financing Update with two accredited investors

Fathom Holdings entered into a Third Omnibus Amendment to its Senior Secured Convertible Promissory Notes, extending the maturity date from November 1, 2026, to November 30, 2026. The amendment defers all accrued and unpaid interest until the new maturity date and introduces a weekly extension fee of 0.5% of the outstanding principal amount.

Counterparty
two accredited investors
Term
through Nov 30, 2026
4:06 PM ET 10-Q
Financial Results Slr Hc BDC LLC

Slr Hc BDC Q3 2026 Results: Net Income $761K, Up 24.3% YoY

For the nine months ended September 30, 2026, SLR HC BDC LLC reported total investment income of $7.1 million and net investment income of $3.1 million. The company's net asset value per unit decreased slightly to $20.87 from $21.11 at the end of 2025, while total unitholders' capital grew to $60.7 million due to $16.7 million in capital contributions.

Key figure
Net income $761K · +24.3% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.